ArticleBioNanoScience2026
A Computational Modeling for Reconfigurable Biosensors.
Article in BioNanoScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For the first time ever reported, we present a multiscale modeling approach combining molecular dynamics simulations of probe-target binding with TCAD simulations of Reconfigurable Field Effect Transistors (RFETs). Field-effect transistor biosensors detect biomolecules by channel surface potential as affected by analyte charge. However, fixed channel doping limits them to sense either positive or negative targets. RFETs, based on doping-free nanowires, overcome this limitation by switching dynamically between n- and p-type modes. Recently proposed as a novel class of reconfigurable devices, RFETs remain almost unexplored as biosensors. Their intrinsic reconfigurability and high surface-to-volume ratio make them ideal for dual-polarity and high-sensitivity detection. To demonstrate RFET adaptability, we use both negatively and positively charged analytes, with two distinct recognition elements - aptamer and enzyme - highlighting the device's ability to detect targets of opposite polarity through different binding mechanisms. The proposed multiscale framework establishes a direct link between molecular-scale binding phenomena and device-level electrical response, providing mechanistic insight into the sensing process and supporting the rational design of RFET-based biosensors. More broadly, the proposed methodology applies to a wide range of charge-based field-effect biosensors and supports device optimization and the prediction of experimentally observable trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.